NICE recommends Novartis’ Piqray therapy
Piqray is a targeted treatment for thousands of advanced breast cancer patients
Read More
Tag: Piqray
EU regulators approve Novartis’ breast cancer combo
Piqray in combination with fulvestrant is the first treatment for tumours with a PIK3CA mutation
Read More
New vaccine for Ebola among CHMP recommendations
The vaccine could be Janssen’s first to win EU approval
Read More
FDA approval for Novartis’ Piqray
The FDA approval is based on a Phase III trial, SOLAR-1, in which the combination nearly doubled median progression free survival.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
